Pekin Hardy Strauss’s ClearPoint Neuro CLPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.39M Buy
277,915
+134,540
+94% +$2.02M 0.3% 87
2026
Q2
$2.56M Buy
143,375
+3,000
+2% +$37.5K 0.23% 117
2026
Q1
$1.28M Buy
+140,375
New +$1.77M 0.13% 181
2025
Q3
– Sell
-50,575
Closed -$604K – 413
2025
Q2
$604K Buy
50,575
+1,750
+4% +$22K 0.07% 223
2025
Q1
$581K Buy
48,825
+575
+1% +$8.94K 0.07% 229
2024
Q4
$742K Hold
48,250
– – 0.09% 197
2024
Q3
$541K Buy
+48,250
New +$462K 0.07% 230

Other funds holding CLPT

Pekin Hardy Strauss's CLPT Position: Q3 2026 in Review

Pekin Hardy Strauss increased its ClearPoint Neuro (CLPT) stake by 94% in Q3 2026, buying an estimated $2.02M and bringing the position to 277,915 shares worth $3.39M. The position accounts for 0.3% of the portfolio, ranked #87.

Pekin Hardy Strauss first reported a position in CLPT in Q3 2024 and has held it in 7 quarters since. 126 funds tracked by Wall St. Rank hold CLPT as of Q3 2026.

  • Pekin Hardy Strauss held 277,915 shares of ClearPoint Neuro worth $3.39M as of Q3 2026.
  • Pekin Hardy Strauss bought 134,540 ClearPoint Neuro shares in Q3 2026, an estimated $2.02M.
  • ClearPoint Neuro made up 0.3% of Pekin Hardy Strauss's portfolio in Q3 2026, its #87 holding.
  • Pekin Hardy Strauss first reported a position in ClearPoint Neuro in Q3 2024 and has held it in 7 quarters since.
  • 126 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q3 2026.

Based on Pekin Hardy Strauss's 13F filing for Q3 2026, filed 2 Nov 2026.